Shares of Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) shot up 7% during trading on Tuesday . The company traded as high as $4.46 and last traded at $4.45. 2,004 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 14,696 shares. The stock had previously closed at $4.16.
Genenta Science Price Performance
The stock's 50 day simple moving average is $3.90 and its 200 day simple moving average is $4.35.
Hedge Funds Weigh In On Genenta Science
Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new position in Genenta Science in the 4th quarter worth about $46,000. Algebris UK Ltd boosted its stake in shares of Genenta Science by 122.2% during the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after purchasing an additional 55,000 shares in the last quarter. Finally, Allianz SE bought a new position in shares of Genenta Science during the fourth quarter valued at approximately $444,000. 15.13% of the stock is currently owned by institutional investors.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
